Citi analyst Daniel Grosslight lowered the firm’s price target on Owens & Minor to $7 from $11 and keeps a Buy rating on the shares. The firm says headwinds in diabetes weighed on the company’s Q2 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMI: